Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SIGA TechnologiesSIGA 66 Days Payable is 110.63 as of Mar. 2026, which is 158% above its 10-year median of 42.80. GuruFocus rates SIGA with a GF Score™ of 66/100 and a GF Value™ of $4.49 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 925 Drug Manufacturers companies, SIGA Technologies ranks worse than 87.46% on this metric.
The historical rank and industry rank for SIGA Technologies's Days Payable or its related term are showing as below:
SIGA'
s Days Payable Range Over the Past 10 Years
Min: 5.78 Med: 42.8 Max: 485.37
Current: 32.78
During the past 13 years, SIGA Technologies's highest Days Payable was 485.37. The lowest was 5.78. And the median was 42.80.
SIGA's Days Payable is ranked worse than 87.46% of 925
companies
in the Drug Manufacturers industry
Industry Median: 90.38
vs SIGA: 32.78
SIGA Technologies's Days Payable
declined
from Mar. 2025 (742.13) to Mar. 2026 (110.63).
It may suggest that SIGA Technologiesaccelerated paying its suppliers.
SIGA Technologies Days Payable Related Terms
SIGA Technologies Days Payable Historical Data
* Premium members only.
The historical data trend for SIGA Technologies's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, SIGA Technologies's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SIGA Technologies Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, SIGA Technologies's Days Payable distribution charts can be found below:
* The bar in red indicates where SIGA Technologies's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
SIGA Technologies's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SIGA Technologies (SIGA) has a Days Payable of 110.63 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on SIGA Technologies and its competitors. This is 158% above median its historical median of 42.80. Over the past decade, SIGA Technologies' Days Payable has ranged from 5.78 to 485.37. According to the industry distribution chart, SIGA Technologies ranks #809 out of 925 companies in the Drug Manufacturers industry, placing it in the top 87.5%.
Is SIGA Technologies' Days Payable too high?
SIGA Technologies' current Days Payable of 110.63 is 158% above median its 10-year median of 42.80. Over the past 10 years, this metric has ranged from a low of 5.78 to a high of 485.37. The Drug Manufacturers industry median Days Payable is 90.38. SIGA Technologies' value of 110.63 is 22.4% above this industry median. Based on the distribution chart, SIGA Technologies ranks #809 out of 925 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, SIGA Technologies has a GF Score™ of 66/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does SIGA Technologies' Days Payable compare to AKBA and TKNO?
According to the Drug Manufacturers industry distribution chart, SIGA Technologies ranks #809 out of 925 companies for Days Payable. This places SIGA Technologies in the lower half of its industry. The industry median Days Payable is 90.38. SIGA Technologies' value of 110.63 is 22.4% above this benchmark. Historically, SIGA Technologies' own Days Payable has ranged from 5.78 to 485.37 over the past decade. While the company's 10-year median is 42.80 vs. the industry median of 90.38, SIGA Technologies has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.38, based on 925 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. SIGA Technologies's current Days Payable of 110.63 is 22.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on SIGA Technologies and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. SIGA Technologies's current Days Payable is 110.63, which is 158% above median its own 10-year median of 42.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SIGA Technologies stock overvalued right now?
Based on GuruFocus' analysis, SIGA Technologies (SIGA) is currently considered Modestly Undervalued. The stock's GF Value™ is $4.49, compared to a current price of $3.49 — trading 22.3% below its estimated fair value. The current Days Payable is 110.63, which is 158% above median its 10-year median of 42.80 and 22.4% above the Drug Manufacturers industry median of 90.38. SIGA Technologies' overall GF Score™ is 66/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For SIGA Technologies (SIGA), the current Days Payable is 110.63 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is SIGA Technologies (SIGA) Overvalued in 2026?
Based on GuruFocus' analysis, SIGA Technologies stock appears to be undervalued.
The current stock price of $3.49 is trading 22.3% below its estimated GF Value™ of $4.49.
GuruFocus considers SIGA Technologies to be Modestly Undervalued.
Key valuation signals for SIGA:
Days Payable: 110.63 (158% above median its 10-year median of 42.80)
GF Value™: $4.49 vs. price of $3.49 (22.3% below fair value)
Industry Position: 22.4% above the Drug Manufacturers median (#809 of 925)
No single metric tells the full story. See the SIGA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
SIGA Technologies Inc a commercial-stage pharmaceutical company. The Company sells its product, TPOX oral TPOXX, also known as tecovirimat, Tecovirimat-SIGA, or TEPOXX (tecovirimat) in certain international markets, to the U.S. Government and international governments (including government-affiliated entities). The Company operates in one single operating and reportable segment, which includes all activities related to the sale of the Company's Oral and IV TPOXX as well as research and development services.
66GF Score
Get the complete analysis for SIGA
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SIGA has been successfully added to your 
